Premier Biomedical, Inc. (OTCQB: BIEI) issued a press release yesterday stating that after several years of mice trials their anti-cancer antibody PBI-5D3H5 has demonstrated great success when paired head to head against commercially available drugs currently on the market. Read what William Hartman, the president and CEO has to say about these substantial results. https://upticknewswire.com/premier-biomedical...niversity/